← All trials
NCT06745336
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2025
- Primary completion
- Jun 15, 2027
- Completion date
- Sep 15, 2027
- First posted
- Dec 20, 2024
- Last posted
- Dec 24, 2024
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Applied Biology, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.